Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 292Urinary Bladder Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 24Carcinoma, Transitional Cell 23Neoplasms 21Breast Neoplasms 20Lung Neoplasms 13Carcinoma, Renal Cell 13Ovarian Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Non-Muscle Invasive Bladder Neoplasms 10Melanoma 9Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Prostatic Neoplasms, Castration-Resistant 7Head and Neck Neoplasms 7Esthesioneuroblastoma, Olfactory 7Esophageal Neoplasms 7Colorectal Neoplasms 7Urethral Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Prostate Cancer Metastatic 5Pancreatic Neoplasms 5Metastatic Castration-resistant Prostate Cancer 5Kidney Neoplasms 5Adenocarcinoma 5Sarcoma 4

Interventions

padeliporfin 5Nivolumab 5Ipilimumab 4Sunitinib 3Specimen Handling 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Abiraterone Acetate 3pembrolizumab 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2abiraterone 2Surveys and Questionnaires 2Radiation Dose Hypofractionation 2Pluvicto 2Paclitaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2vinflunine 1valrubicin 1tislelizumab 1temsirolimus 1sipuleucel-T 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Docetaxel × Genitourinary × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔